REPATHA PUSHTRONEX Rx
Generic Name and Formulations:
Evolocumab 420mg/3.5mL; per system (on-body infusor with prefilled cartridge); soln for SC use; preservative-free.
Indications for REPATHA PUSHTRONEX:
Adjunct to diet and maximally tolerated statin therapy, in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease requiring additional lowering of LDL-C. Adjunct to diet and other LDL-lowering therapies, in patients with homozygous familial hypercholesterolemia (HoFH) requiring additional lowering of LDL-C.
Limitations Of use:
Effect on cardiovascular morbidity and mortality has not been determined.
Give by SC inj into abdomen, thigh, or upper arm; rotate inj sites. HeFH or primary hyperlipidemia: 140mg every 2 weeks or 420mg once monthly. HoFH: (≥13yrs): 420mg once monthly; measure LDL-C levels 4–8 weeks after initiation. To administer 420mg dose: give over 9 mins by using the on-body infusor or as 3 inj consecutively within 30 mins using the prefilled syringe or autoinjector.
HeFH or primary hyperlipidemia: not established. HoFH: <13yrs: not established.
Do not inject into areas that are tender, bruised, red, or indurated. Discontinue if serious allergic reactions occur. Severe renal or hepatic impairment. Pregnancy. Nursing mothers.
Avoid co-administration with other injectable drugs at same inj site.
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.
Nasopharyngitis, URTI, influenza, back pain, inj site reactions.
Single-use prefilled syringe—1; Single-use prefilled SureClick autoinjector—1, 2, 3; Single-use Pushtronex system—1
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|